"An important factor in the Board's consideration of Elliott's recommendation is that we firmly believe the Company has established a strong foundation to drive growth, create value and improve patients' lives," the pharmaceutical firm said in a statement. This foundation is supported by a refreshed management and board and a renewed strategy for its blood disorder drug Ultomiris.
The company said that it has not received any indications of interest and that it will maintain dialogue with its investors.
Price: 112.21, Change: +4.79, Percent Change: +4.46
|Market Chatter: Google to Strictly Implement In-App ...|
|Google Hit by Service Outage Due to Server Crash|
|Analyst Actions: Goldman Sachs Adjusts Price Target ...|
|Market Chatter: ProSight Global Reportedly in Takeov...|
|Colony Capital's Convertible Senior Notes Offering E...|